BioCentury

7:00 AM GMT, Jun 4, 2007
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

Desmoteplase: Not much to go on

While it's not clear what caused last week's failure of the Phase III DIAS-2 trial of Paion AG's desmoteplase to treat acute ischemic stroke, small patient numbers and the lack of a reperfusion endpoint might make it impossible to assess whether the thrombolytic works or not. As a result, Paion estimates that potential approval has been pushed back at least two years.

Paion and partner Forest Laboratories Inc. reported that both doses of desmoteplase missed the primary endpoint of clinical improvement at day 90 vs. placebo in DIAS-2, the same endpoint that was met in the similarly designed Phase II DIAS and DEDAS trials.

"The design and size of the Phase III was based on two Phase II trials, which showed a benefit in the

Read the full 1236 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.